Share buy-back

On June 17, 2019 we commenced, as announced on June 14, 2019, our share buy-back program on the basis of the authorization by the Annual General Meeting 2016.

In the context of this share buy-back program, ordinary shares of Fresenius Medical Care in the total amount of €659 million (excluding fees) were repurchased in the period from June 17, 2019 until April 1, 2020. Accordingly, the share buy-back program was fully completed on April 1, 2020.

In the following we inform you about the number of shares acquired in the context of the share buy-back program.

The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares.

On March 12, 2019 we commenced, as announced on March 11, 2019, our share buy-back program on the basis of the authorization by the Annual General Meeting 2016.

In the context of this share buy-back program, ordinary shares of Fresenius Medical Care in the total amount of €270 million (excluding fees) were repurchased in the period from March 12, 2019 until May 10, 2019. Accordingly, the share buy-back program was fully completed on May 10, 2019.

In the following we inform you about the number of shares acquired in the context of the share buy-back program.

The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares.

On May 28, 2018 we commenced, as announced on May 25, 2018, our share buy-back program on the basis of the authorization by the Annual General Meeting 2016.

In the context of this share buy-back program, ordinary shares of Fresenius Medical Care in the total amount of €37 million (excluding fees) were repurchased in the period from May 28, 2018 until June 8, 2017. Accordingly, the share buy-back program was fully completed on June 8, 2017.

In the following we inform you about the number of shares acquired in the context of the share buy-back program.

TThe own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares in order to neutralize the dilution from the Stock Option Plan 2011.

On December 11, 2017 we commenced, as announced on December 8, 2017, our share buy-back program on the basis of the authorization by the Annual General Meeting 2016.

In the context of this share buy-back program, ordinary shares of Fresenius Medical Care in the total amount of €58 million (excluding fees) were repurchased in the period from December 11, 2017 until December 21, 2017. Accordingly, the share buy-back program was fully completed on December 21, 2017. T

In the following we inform you about the number of shares acquired in the context of the share buy-back program.

The own shares repurchased by the Company will be used for the sole purpose of reducing the registered share capital by cancellation of the repurchased own shares in order to neutralize the dilution from the Stock Option Plan 2011.